---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-055903"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2025-04-18T23:59:59+00:00"
generated_at: "2026-05-23T10:54:21.968193+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Director Robert Hofmeister resigns from Alaunos Therapeutics board effective April 15, 2025

## Summary
- Robert Hofmeister, Ph.D., resigned from the board with immediate effect on April 15, 2025.
- Resignation was not due to any disagreement on operations, policies, or practices.
- No replacement has been named by the company.

## SEC filing metadata
- accession: 0000950170-25-055903
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2025-04-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000095017025055903/0000950170-25-055903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000095017025055903/tcrt-20250415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-055903
- JSON: https://secwatch.observer/filing/0000950170-25-055903.json
- Plain text: https://secwatch.observer/filing/0000950170-25-055903.txt

## Key facts
- Executive change
  Robert Hofmeister resigned as director at Alaunos Therapeutics, Inc..
  - Action: resigned
  - Role: director
  source text: Robert Hofmeister, Ph.D. Resignation On April 15, 2025, Dr. Hofmeister resigned as a member of the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) with immediate effect.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000095017025055903/0000950170-25-055903-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.